Study		Exclusion reasons	Remarks	Reference(s)
HYDRA, 2020	randomized controlled trial		Initially found in Axfors et al. meta-analysis results published by Hernadez et al
BCN PEP-CoV-2-Study 2 (Mitja Lancet-preprint), 2020	randomized controlled trial			Mitja O et al. Lancet preprint
Mohana, 2020	retrospective cohort (claims database)	no control group		Mohana A Int J Infect Dis 2020 Oct 16;S1201-9712(20)32235-9. 10.1016/j.ijid.2020.10.031
Kanran M, 2020	randomized controlled trial	other	randomization process unclear : Thepatients who did not give consent for treatment with HCQ or had a known allergy to HCQ orchloroquine or had another known contraindication to treatment with the study drug, includingretinopathy, G6PD deficiency and QT prolongation served as controls	sultan mehmood kamran medRxiv 10.1101/2020.07.30.20165365
Alberici, 2020	retrospective cohort	other	HCQ efficacy or safety evaluation wasn't a prespecified endpoint	Alberici F Kidney Int 2020 Jul;98(1):20-26. 10.1016/j.kint.2020.04.030